Abstract
A biopharmaceutics drug classification scheme for correlating in vitro drug product dissolution and in vivo bioavailability is proposed based on recognizing that drug dissolution and gastrointestinal permeability are the fundamental parameters controlling rate and extent of drug absorption. This analysis uses a transport model and human permeability results for estimating in vivo drug absorption to illustrate the primary importance of solubility and permeability on drug absorption. The fundamental parameters which define oral drug absorption in humans resulting from this analysis are discussed and used as a basis for this classification scheme. These Biopharmaceutic Drug Classes are defined as: Case 1. High solubility-high permeability drugs, Case 2. Low solubility-high permeability drugs, Case 3. High solubility-low permeability drugs, and Case 4. Low solubility-low permeability drugs. Based on this classification scheme, suggestions are made for setting standards for in vitro drug dissolution testing methodology which will correlate with the in vivo process. This methodology must be based on the physiological and physical chemical properties controlling drug absorption. This analysis points out conditions under which no in vitro-in vivo correlation may be expected e.g. rapidly dissolving low permeability drugs. Furthermore, it is suggested for example that for very rapidly dissolving high solubility drugs, e.g. 85% dissolution in less than 15 minutes, a simple one point dissolution test, is all that may be needed to insure bioavailability. For slowly dissolving drugs a dissolution profile is required with multiple time points in systems which would include low pH, physiological pH, and surfactants and the in vitro conditions should mimic the in vivo processes. This classification scheme provides a basis for establishing in vitro-in vivo correlations and for estimating the absorption of drugs based on the fundamental dissolution and permeability properties of physiologic importance.
Similar content being viewed by others
REFERENCES
N.F.H. Ho, H.P. Merkle, and W.I. Higuchi. Quantitative, Mechanistic and Physiologically Realistic Approach to the Biopharmaceutical Design of Oral Drug Delivery Systems. Drug Dev. and Ind. Pharm. 9:1111–1184 (1983).
P.J. Sinko, G.D. Leesman, and G.L. Amidon, Predicting fraction dose absorbed in humans using a macroscopic mass balance approach, Pharm. Res., 8:979–988 (1991).
D-M Oh, R.L. Curl, and G.L. Amidon. Estimating the Fraction Dose Absorbed From Suspensions of Poorly Soluble Compounds in Humans: A Mathematical Model. Pharm. Res. 10:264–270 (1993)
J.B. Dressman and D. Fleisher. Mixing-tank Model for Predicting Dissolution Rate Control of Oral Absorption. J. Pharm. Sci. 75:109–116 (1986).
R.B. Hintz and K.C. Johnson. The Effect of Particle Size Distribution on Dissolution and Oral Absorption. Int J Pharm, 51:9–17 (1989).
G.D. Leesman, R.L. Oberle, G.L. Amidon, The Use of Error Functions in Characterizing Gastric Emptying in Humans, Pharm Res, 8:S-254 (1991).
R.L. Oberle, The Influence of the Interdigestive Migrating Myoelectric Complex on the Gastric Emptying of Liquids and Oral Absorption of Cimetidine, Ph.D. Thesis, The University of Michigan, Ann Arbor, MI (1988).
R.L. Oberle, and G.L. Amidon, The influence of variable gastric emptying and intestineal transit rates on the plasma level curve of cimetidine; an explaination for the double peak phenomenon, J Pharmacok Biopharm, 15:529 (1987).
R.L. Oberle, T-S Chen, C. lloyd, J.L. Barnett, C. Owyang, J. Meyer, G.L. Amidon, The Influence of the Interdigestive Migrating Myoelectrc Complex on the Gastric Emptying of Liquids. Gastroenterology, 99:1275–1282 (1990).
P.J. Sinko, G.D. Leesman, and G.L. Amidon, Mass Balance Approaches for Estimating the Intestinal Absorption and Metabolism of Peptides and Analogues: Theoretical Development and Applications, Pharm. Res. 10:271–275 (1993).
G.L. Amidon, P.J. Sinko, D. Fleisher, Estimating human oral fraction dose absorbed: A correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds, Pharm. Res. 5:651–654 (1988).
D-M Oh, Estimating Oral Drug Absorption in Humans, Ph.D. Thesis. The University of Michigan, Ann Arbor, MI. (1991).
J.R. Crison. Estimating the Dissolution and Absorption of Water Insoluble Drugs in the Small Intestine. Ph.D. Thesis, The University of Michigan, Ann Arbor, MI. (1993).
E.L. Cussler, Diffusion, Mass transfer in fluid systems, Cambridge University Press, NY (1986).
H. Lennernas, O. Ahrenstedt, R. Hallgren, L. Knutson, M. Ryde, L.K. Paalzow, Regional Jejunal Perfusion, A New in Vivo Approach to Study Oral Drug Absorption in Man, Pharm Res, 9:1243–1255 (1992).
J.B. Dressman, D. Fleisher, and G.L. Amidon. Physicochemical Model for Dose-Dependent Drug Absorption, J Pharm Sci, 73: 1274 (1984).
E.M. Topp, Physiological Flow Models for Intestinal Absorption and Plasma Kinetics of Aspirin, Thesis, The University of Michigan (1986).
G.D. Leesman, P.J. Sinko, and G.L. Amidon, Simulation of Oral Drug Absorption: Gastric Emptying and Gastrointestinal Motility, in: Pharmacokinetics, P.W. Welling and F.L.S. Tse, Editors, Marcel Dekker, Inc., (NY) 1988, Ch 6, p 267.
P.F. Ni, N.F.H. Ho, J.L. Fox, H. Leuenberger, and W.I. Higuchi. Theoretical Model Studies of Intestinal Drug Absorption V. Non-Steady-State Fluid Flow and Absorption. Int. J. Pharm., 5:33–47 (1980).
G.L. Amidon, J. Kou, R.L. Elliott, and E.N. Lightfoot, Analysis of Models for Determining Intestinal Wall Permeabilities, J Pharm Sci, 69: 1370 (1980).
J.H. Kou, D. Fleisher, and G.L. Amidon, Calculation of the aqueous diffusion layer resistence for absorption in a tube: application to intestinal membrane permeability determination, Pharm Res, 8:298 (1991).
V.G. Levich, Physico-Chemical Hydrodynamics, Prentice-Hall, Englewood Cliffs, NJ (1962).
H. Lennernäs, Intestinal Absorption Characteristics of Three Model Drugs, Thesis, The University of Uppsala, Sweden (1992).
U. Fagerholm, L. Borgström, Ö. Ahrenstedt, H. Lenneräs, The lack of effect of induced net fluid absorption on the in vivo permeability of terbutaline in the human jejunum. J. Drug Targeting. In press (1995).
H. Lenneräs, D. Nilsson, S-M. Aquilonius, O. Ahrenstedt, L. Knutson, L.K. Paalzow, The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. Br. J. Clin. Pharmacol., 35:243–250 (1993).
H. Lenneräs, Ö. Ahrenstedt, A-L. Ungell, Intestinal drug absorption during induced net water absorption in man; A mechanistic study using antipyrine, atenolol, and enalaprilat. Br. J. Clin. Pharmacol., 37:589–596 (1994).
A.J. Jounela, P.J. Pentikainen, A. Sothman, Effect of Particle Size on the Bioavailability of Digoxin, Europ J clin Pharmacol, 8:365–370 (1975).
M. Kraml, J. Dubuc, R. Gaudry, Gastrointestinal Absorption of Griseofulvin: II. Influence of Particle Size in Man, Antibiotics and Chemotherapy, 12:239–242 (1962).
H.M. Abdou, Dissolution, Bioavailability, & Bioequivalence, A. Gennaro, B. Migdalof, G.L. Hassert and T. Medwick (Eds), Mack Publishing Co., Easton PA (1989).
V.P. Shah, J.J. Konecny, R.L. Everett, B. McCullough, A.C. Noorizadeh, J.P. Skelly, In Vitro Dissolution Profile of Water-Insoluble Drug Dosage Forms in the Presence of Surfactacts, Pharm Res., 6:612:618 (1989).
P.E. Macheras, M.A. Koupparis and S.G. Antimisiaris. Effect of Temperature and Fat Content on the Solubility of Hydrochlorothiazide and Chlorothiazide im Milk. J. Pharm. Sci., 78:933–936 (1989).
The Merck Index, Tenth Edition, Merck & Co., Inc., Rahway, NJ (1983).
S.S. Davis, J.G. Hardy and J.W. Fara, Transit of Pharmaceutical Dosage Forms Through the Small Intestine, Gut, 27:886–892 (1986).
Author information
Authors and Affiliations
Additional information
Vinod P. Shah: The manuscript represents the personal opinions of this author and does not necessarily represent the views or policies of the Agency.
Rights and permissions
About this article
Cite this article
Amidon, G.L., Lennernäs, H., Shah, V.P. et al. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability. Pharm Res 12, 413–420 (1995). https://doi.org/10.1023/A:1016212804288
Issue Date:
DOI: https://doi.org/10.1023/A:1016212804288